Dim3 Nutrow Trial to start soon in Texas, United States
Dim3, through its subsidiary Dim3 US, has built a partnership with CHI-St. Joseph Hospital, Bryan, Texas.
As a strong partner, CHI-St. Joseph Hospital is part of a large hospital network and close to the Texas A&M University. The objective of this partnership is to evaluate Dim3’s clinical nutrition solutions in routine use.
The study will be assessing the usability and the potential financial and clinical gains. The protocol has been designed and defined. Both partners are preparing the kickoff of this trial which should start in January 2019
Dim3 targets the US market for the commercialization of its solutions. This partnership is a key milestone to obtain the FDA approval to market in the US.
Clinical nutrition management can be challenging for healthcare institutions. For instance, the gap between prescribed and really delivered nutrition in intensive care is recognized as a major problem due to morbidity impacts. Nutrow, Dim3’s solution, allows the detection and correction of this gap with positive clinical consequences for the patients and for the hospitals.
Dim3 aims at addressing the nutrition-related challenges by providing user-friendly tools for healthcare professionals to assess, manage and monitor patients’ nutritional status.
Dim3 in the press (FR only): http://www.lalibre.be/economie/libre-entreprise/la-societe-liegeoise-dim3-attaque-le-marche-americain-via-le-texas-5ba3cd11cd7055ac02373391
If you would like to have more information, please contact us.
